von Bismarck, OlgaOlgavon BismarckDankowski, TheresaTheresaDankowskiAmbrosius, BjörnBjörnAmbrosiusHessler, NicoleNicoleHesslerAntony, GiselaGiselaAntonyZiegler, AndreasAndreasZieglerHoshi, Muna-MiriamMuna-MiriamHoshiAly, LilianLilianAlyLuessi, FelixFelixLuessiGroppa, SergiuSergiuGroppaKlotz, LuisaLuisaKlotzMeuth, Sven G.Sven G.MeuthTackenberg, BjörnBjörnTackenbergStoppe, MurielMurielStoppeThen Bergh, FlorianFlorianThen BerghTumani, HayrettinHayrettinTumaniKümpfel, TaniaTaniaKümpfelStangel, MartinMartinStangelHeesen, ChristophChristophHeesenWildemann, BrigitteBrigitteWildemannPaul, FriedemannFriedemannPaulBayas, AntoniosAntoniosBayasWarnke, ClemensClemensWarnkeWeber, FrankFrankWeberLinker, Ralf A.Ralf A.LinkerZiemann, UlfUlfZiemannZettl, Uwe K.Uwe K.ZettlZipp, FraukeFraukeZippWiendl, HeinzHeinzWiendlHemmer, BernhardBernhardHemmerGold, RalfRalfGoldSalmen, AnkeAnkeSalmen2024-10-252024-10-252018https://boris-portal.unibe.ch/handle/20.500.12422/159072Objective: To assess clinical characteristics, distribution of disease-modifying treatments (DMTs), and neuropsychological symptoms in a large cohort of patients with early-stage MS. Methods: The German National MS Cohort is a multicenter prospective longitudinal cohort study that has recruited DMT-naive patients with clinically isolated syndrome (CIS) and relapsing-remitting MS (RRMS) since 2010. We evaluated their baseline characteristics and the prevalence of neuropsychological symptoms. Results: Of 1,124 patients, with a 2.2:1 female-to-male ratio and median age at onset of 31.71 years (interquartile range [IQR]: 26.06–40.33), 44.6% and 55.3% had CIS and RRMS, respectively. The median Expanded Disability Status Scale (EDSS) score at baseline was 1.5 (IQR: 1.0–2.0). A proportion of 67.8% of patients started DMT after a median time of 167.0 days (IQR 90.0–377.5) since the first manifestation. A total of 64.7% and 70.4% of the 762 patients receiving early DMT were classified as CIS and RRMS, respectively. Fatigue, depressive symptoms, and cognitive dysfunction were detected in 36.5%, 33.5%, and 14.7% of patients, respectively. Conclusion: Baseline characteristics of this large cohort of patients with early, untreated MS corroborated with other cohorts. Most patients received early DMT within the first year after disease onset, irrespective of a CIS or RRMS diagnosis. Despite the low EDSS score, neuropsychological symptoms affected a relevant proportion of patients.en600 - Technology::610 - Medicine & healtharticle10.7892/boris.1124242951170510.1212/NXI.0000000000000446